Randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder
Akira Nishimura; Yutaka Aritomi; Kiyofumi Sasai; Tadayuki Kitagawa; Atul R. Mahableshwarkar
Author Information: Takeda Pharmaceutical Company Limited
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.